SCHEMBL16637074

SCHEMBL16637074

CC(C)(C)OC(=O)N1CCN(c2ncnc3[nH]cc(-c4ccccc4Cl)c23)CC1

nearest known ligand 0.61

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 7/20 0.61
CNR2 P34972 3/20 0.57
CNR1 P21554 2/20 0.57
KIT P10721 4/20 0.55
BTK Q06187 2/20 0.49
STK4 Q13043 3/20 0.48
STK3 Q13188 3/20 0.48
AKT1 P31749 2/20 0.47
AKT1S1 Q96B36 1/20 0.47
SMARCA2 P51531 1/20 0.46
SMARCA4 P51532 1/20 0.46
PBRM1 Q86U86 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30295133 0.89 LRRK2 (0.61) LRRK2CNR2CNR1KITBTK
SCHEMBL29247128 0.89 LRRK2 (0.61) LRRK2CNR2CNR1KITBTK
SCHEMBL30295134 0.89 LRRK2 (0.61) LRRK2CNR2CNR1KITBTK
SCHEMBL28367334 0.87 AKT1 (0.55) CNR2CNR1KITBTKAKT1
SCHEMBL29247486 0.85 KIT (0.55) LRRK2CNR2CNR1KITBTK
SCHEMBL30372597 0.85 KIT (0.55) LRRK2CNR2CNR1KITBTK
SCHEMBL28129919 0.85 LRRK2 (0.61) LRRK2CNR2KITSTK4STK3
SCHEMBL16636776 0.82 LRRK2 (0.66) LRRK2CNR2KITSTK4STK3
SCHEMBL28367843 0.81 AKT1 (0.57) KITBTKAKT1AKT1S1
SCHEMBL2253309 0.81 AKT1 (0.57) KITBTKAKT1AKT1S1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-02-25 US disclosed
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-10-24 US disclosed
US-20240043441-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-02-08 US disclosed
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2024-01-23 US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 US disclosed
US-20220242875-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2022-08-04 US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 US disclosed
WO-2016044772-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2016-03-24 WO disclosed
WO-2016044772-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2016-03-24 WO disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 US disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 WO disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C KRAS, NRAS, HRAS LRRK2 53/4885CNR2 4274/4885CNR1 3613/4885
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C KRAS, NRAS, HRAS LRRK2 63/4885CNR2 3665/4885CNR1 2883/4885
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS LRRK2 63/4885CNR2 3665/4885CNR1 2883/4885
US-20150239900-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS LRRK2 40/4885CNR2 4236/4885CNR1 3222/4885
US-20230212183-A9 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS LRRK2 40/4885CNR2 4236/4885CNR1 3222/4885
US-20240043441-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS LRRK2 40/4885CNR2 4236/4885CNR1 3222/4885
US-20230303586-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS LRRK2 40/4885CNR2 4236/4885CNR1 3222/4885
US-20220242875-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS LRRK2 40/4885CNR2 4236/4885CNR1 3222/4885
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER KRAS, TP53, HRAS LRRK2 2016/4885CNR2 4414/4885CNR1 4396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.